Hyperfine (HYPR) Investor Presentation summary

Market opportunity and value proposition

• First FDA-cleared, AI-powered portable MR brain imaging system with proprietary technology and broad accessibility across care settings.

• $6B+ US market opportunity in outpatient settings by 2025, with further expansion to $16B+ in community settings by 2026.

• Compelling clinical and economic value, with reimbursement in place and attractive revenue growth and gross margin profile.

• Platform technology aims to address large unmet healthcare needs and expand to additional anatomies.

Product innovation and technology

• Swoop system offers portable, compact MRI imaging, enabling scans at the point of care without specialized siting or personnel.

• Next Gen Swoop system powered by Optive AI delivers image quality approaching conventional MRI, supporting confident diagnoses.

• Optive AI software uses deep learning to enhance image clarity and reduce noise, with 10 generations of AI-enabled software and multiple FDA clearances.

• Over 200 issued patents and broad FDA clearance for brain imaging in patients of all ages.

Commercial strategy and execution

• Over 190 Swoop systems installed globally, with direct sales in the US and distributors in 10+ international markets.

• Hospital business targets critical care, emergency, and clinics, with 1–1.5 year breakeven and potential for multiple system placements per hospital.

• Office business offers affordable, plug-and-play MRI with short sales cycles and incremental revenue opportunities for neurology practices.

• International expansion includes Optive AI software launch in 10 European languages and regulatory clearances expected in Europe, Canada, and India.